Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
Bullfrog AI Holdings, Inc. (NASDAQ: BFRG) is a dynamic clinical-phase biotechnology company that leverages the power of artificial intelligence and machine learning to advance medical research and improve human health. The company's proprietary platform, bfLEAP™, addresses the challenges of scalability and flexibility in data analysis, offering researchers and clinicians a more precise, multi-dimensional understanding of complex biological data.
Bullfrog AI's core business involves utilizing its AI-driven platform to enhance drug development for both internal projects and collaborations with external partners. The company stands at the forefront of AI-driven drug development, using its technology to create and analyze networks of biological, clinical, and real-world data. This innovation spans from early discovery stages to late-stage clinical trials, aiming to streamline data analytics in therapeutic development, thereby reducing failure rates and development costs.
One of the company's recent significant achievements includes a collaboration with the Lieber Institute for Brain Development (LIBD). This partnership successfully stratified brain expression data from over 2,800 brain samples, offering novel insights into psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Through advanced graph analytics and causal AI, this collaboration identified potential molecular subtypes, biomarkers, and drug targets for these conditions.
Financially, Bullfrog AI recently conducted a public offering of 1,507,139 shares of common stock, priced at $3.782 per share, raising approximately $5.7 million before underwriting discounts and offering expenses. WallachBeth Capital LLC acted as the sole book-running manager for this offering, which is expected to close on February 5, 2024, subject to customary closing conditions.
For more information:
- Website: bullfrogai.com
- LinkedIn: Bullfrog AI on LinkedIn
- Investor Contact: Dave Gentry, RedChip Companies, Inc., BFRG@redchip.com, 800-733-2447
BullFrog AI Holdings (Nasdaq: BFRG) announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole, signed on October 13, 2022. This world-wide, royalty-bearing license allows BullFrog to commercialize N-substituted prodrugs that improve solubility and bioavailability compared to the original compound. The prodrugs target oncology treatments, notably glioblastoma, leveraging BullFrog's AI technology to enhance drug development efficiency. Vin Singh, the CEO, emphasized the potential of this asset in their oncology pipeline. BullFrog AI is committed to advancing precision medicine through machine learning in drug development, aiming to reduce costs and improve patient outcomes.
RedChip Companies will feature interviews with BullFrog AI (NASDAQ:BFRG) and Alarum Technologies Ltd. (NASDAQ:ALAR) on The RedChip Money Report this Saturday, April 15, at 7 p.m. ET. The program will be broadcast on Bloomberg TV, which reaches approximately 73 million homes in the U.S.
View the interviews online at:
BullFrog AI is focused on precision medicine using its proprietary bfLEAP™ AI platform to enhance drug development and patient therapy matching. Alarum Technologies provides internet access solutions, including privacy and cybersecurity for enterprises and consumers.
GAITHERSBURG, Md., April 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, a digital technology company focused on precision medicine, announced CEO Vin Singh's participation in a panel at the Money Show in Las Vegas on April 24-26, 2023. The panel, titled 'Innovators in a Dynamic Tech Environment - A Perfect Fit for Your Portfolio,' will occur at 3:10 p.m. PT on April 24 and 1:15 p.m. PT on April 25.
Singh plans to discuss the company's vision and how its machine learning technology enhances drug development. Following its recent Nasdaq IPO, BullFrog AI aims to accelerate progress in the coming quarters. The Money Show connects investors with financial experts, providing insights and strategies.
For more details, visit the company's website.
On April 6, 2023, BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) announced that CEO Vin Singh will appear on The RedChip Money Report on Bloomberg TV on April 8, 2023, at 7 p.m. ET. The broadcast reaches approximately 73 million homes in the U.S. Singh will discuss the company’s exclusive licensing agreement with Johns Hopkins’ Applied Physics Lab for its AI technology in drug development, the current development pipeline, and potential partnership opportunities.
BullFrog AI specializes in precision medicine using machine learning. Its proprietary bfLEAP™ platform aims to enhance drug development success by predicting patient responses, ultimately reducing development costs and improving patient outcomes.
On April 5, 2023, RedChip Companies announced that interviews featuring BullFrog AI (NASDAQ:BFRG) and Sharps Technology (NASDAQ:STSS) will air on The RedChip Money Report on Bloomberg TV this Saturday, April 8, at 7 p.m. ET. The show reaches approximately 73 million households in the U.S.
These interviews aim to provide insights into the companies' innovative approaches and market strategies. BullFrog AI focuses on AI-driven drug development using its proprietary bfLEAP™ platform, while Sharps Technology specializes in innovative drug delivery systems and safety features in syringe technologies.
BullFrog AI Holdings (Nasdaq: BFRG; BFRGW) has announced a worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for patented technology to enhance its bfLEAP™ platform, which focuses on accelerating therapeutic development. This platform employs advanced analytics to improve the identification of relevant data, thereby potentially reducing development costs and failure rates for new therapeutics. The licensed technologies include Prometheus and Seagull, which enhance data analysis capabilities. BullFrog aims to use this technology to streamline drug development and improve patient outcomes.
BullFrog AI Holdings (NASDAQ: BFRG; BFRGW) has announced its listing on the Webull platform, connecting with over 1.3 million active investors. This collaboration aims to enhance communication with shareholders by providing real-time updates on corporate activities such as news, earnings, and presentations. Founder and CEO Vin Singh expressed excitement about the partnership, emphasizing the efficiency of digital communications for reaching investors. BullFrog AI focuses on precision medicine and AI-driven drug development, using its proprietary bfLEAP™ platform to optimize therapeutic outcomes and reduce costs in pharmaceutical development.
BullFrog AI Holdings (NASDAQ:BFRG; BFRGW) has announced a collaboration with the J. Craig Venter Institute to co-develop a synthetic HSV-1 virus targeting colorectal cancer. This partnership aims to utilize BullFrog's bfLEAP™ AI platform for optimizing cancer therapeutics with reduced toxicity while enhancing efficacy. With colorectal cancer being the third most prevalent cancer in the U.S., this project seeks to create a novel class of treatments, potentially revolutionizing precision medicine. The initiative emphasizes BullFrog's commitment to advancing drug development through AI innovation.
On February 16, 2023, Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) successfully completed its IPO, raising approximately $8.4 million by selling 1,297,318 units at $6.50 per unit. Each unit comprises one share of common stock and two types of warrants. The offering includes an underwriters' option to purchase additional shares, amounting to 15% of the units sold, within 45 days. This capital will support Bullfrog AI's mission to advance precision medicine through machine learning technologies. WallachBeth Capital and Kingswood served as the joint bookrunners for this offering.
Bullfrog AI Holdings (NASDAQ:BFRG; BFRGW) has successfully closed its initial public offering, securing approximately $8.4 million through the sale of 1,297,318 units priced at $6.50 each. Each unit includes one share of common stock and two warrants with exercise prices of $7.80 and $8.125. Trading for the shares and tradeable warrants commenced on February 14, 2023. The underwriters hold an option to purchase up to 15% additional shares within 45 days. Bullfrog AI focuses on using machine learning for precision medicine, partnering with major institutions like Johns Hopkins University to enhance drug development.
FAQ
What is the current stock price of BULLFROG AI HLDGS (BFRG)?
What is the market cap of BULLFROG AI HLDGS (BFRG)?
What does Bullfrog AI Holdings, Inc. do?
What is bfLEAP?
What are Bullfrog AI's recent achievements?
How does Bullfrog AI's technology benefit drug development?
What financial activities has Bullfrog AI recently conducted?
Who managed Bullfrog AI's recent public offering?
How does Bullfrog AI collaborate with other institutions?
What is the focus of Bullfrog AI's collaboration with the Lieber Institute for Brain Development?
Where can I find more information about Bullfrog AI?
Who is the investor contact for Bullfrog AI?
